Generic Name and Formulations:
Clofazimine 50mg; soft gel caps.
Novartis Pharmaceuticals Corp
Indications for LAMPRENE:
Lepromatous leprosy, including dapsone-resistant, and/or complicated by erythema nodosum leprosum.
Take with meals. Dapsone-sensitive: 100mg daily with 2 other antileprosy drugs for ≥2 years until skin smears negative, then use antileprosy monotherapy. Dapsone-resistant: 100mg daily with ≥1 other antileprosy drug for 3 years, then 100mg daily as monotherapy. Erythema nodosum: 100–200mg daily in combination with baseline antileprosy treatment and steroids as clinically indicated; if administered at 200mg dose, taper to 100mg as soon as possible; see full labeling.
Abdominal obstruction and other GI disorders (eg, abdominal pain, nausea, vomiting, diarrhea); if occurs, consider reducing dose, increasing dosing interval, or discontinuing. QT prolongation: monitor ECGs. Psychological effects of skin discoloration: monitor for depression or suicidal ideation. Elderly. Pregnancy; verify status prior to initiation. Females of reproductive potential should use effective contraception and males (condoms) during treatment and for at least 4 months after completion. Nursing mothers: not recommended.
Dapsone may inhibit antiinflammatory activity. Concomitant with other QT prolonging drugs or with bedaquiline may cause additive QT prolongation.
Skin and body fluid discoloration (conjunctivae, tears, urine, fecal, sputum, or sweat), ichthyosis, dryness, rash, pruritus, diarrhea, nausea, vomiting, GI intolerance, abdominal/epigastric pain; elevated blood glucose or ESR; QT prolongation, Torsades de Pointes.
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States